
TSX

# LIFE

# EVOLVE GLOBAL HEALTHCARE ENHANCED YIELD FUND

## Access 20 Global Healthcare Companies

| | |
|---|---|
| TICKERS: LIFE (Hedged); LIFE.B (Unhedged); LIFE.U (USD) | MANAGEMENT FEE[1]: 0.45% |
| FUNDSERV CODES: EVF170 (Class F); EVF171 (Class A) | MUTUAL FUND CLASS A TRAILER[1]: 1.00% |
| EXCHANGE: Toronto Stock Exchange (TSX) | TARGET YIELD[2]: 7.00% |
| INCEPTION DATE: October 25, 2017 (LIFE & LIFE.B) | DISTRIBUTION FREQUENCY: Monthly |
| November 27, 2019 (LIFE.U) | INDEX REBALANCING: Quarterly |
| July 7, 2020 (EVF170 & EVF171) | |

LIFE seeks to replicate the performance of the Solactive Global Healthcare 20 Index Canadian Dollar Hedged, while mitigating downside risk by writing covered call options on up to 33% of the portfolio securities. The level of covered call option writing may vary based on market volatility and other factors.

## REASONS TO BUY:

### 1. GLOBAL OPPORTUNITIES IN HEALTHCARE

- Increasing population
- Aging population
- Increased global prosperity

### 2. DIVERSIFICATION

- Portfolio of 20 global healthcare companies
- Large bluechip companies

### 3. COVERED CALL STRATEGY

- Actively managed
- Increased yield potential
- Helps mitigate risk

## PORTFOLIO METRICS[3]:

| | |
|---|---|
| Average Market Cap: $220 billion | Average Portfolio Dividend Yield: 2.46% |
| Number of Holdings: 20 | Average Price to Earnings: 30.7 |
| Target Yield[2]: 7.00% | 5 Year Average Return on Equity: 32.9% |

[1] Plus applicable sales taxes
[2] Estimate only. Actual yield changes daily based on market conditions. Target yield is gross of MER.

Source: Bloomberg, Morningstar, as at March 31, 2021.

TSX **LIFE**

# EVOLVE GLOBAL HEALTHCARE ENHANCED YIELD FUND

Evolve ETFs

## PERFORMANCE (%)

| TOTAL RETURNS* | 1 MTH | YTD | 1 YR | 2 YR | 3 YR | SI** |
|---|---|---|---|---|---|---|
| LIFE (HEDGED) | 3.00 | 1.18 | 18.54 | 11.37 | 11.52 | 8.32 |
| LIFE.B (UNHEDGED) | 0.89 | -1.08 | 9.39 | 9.32 | 12.82 | 9.88 |
| LIFE.U (USD) | 2.17 | 0.19 | 22.50 | - | - | 10.99 |

Source: Bloomberg, as at March 31, 2021. ** Performance since inception of LIFE and LIFE.B on October 25, 2017 and LIFE.U on November 27, 2019.

## SECTOR ALLOCATION:



| NAME | WEIGHT |
|---|---|
| CONSUMER, NON-CYCLICAL | 100% |

## GEOGRAPHIC ALLOCATION:



| NAME | WEIGHT |
|---|---|
| UNITED STATES | 61% |
| SWITZERLAND | 10% |
| BRITAIN | 10% |
| FRANCE | 5% |
| IRELAND | 5% |
| AUSTRALIA | 5% |
| DENMARK | 5% |

## HOLDINGS INCLUDE:

GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, stryker, CSL, Medtronic, MERCK, Abbott, novo nordisk, AstraZeneca, DANAHER, Johnson & Johnson, SANOFI, NOVARTIS, ThermoFisher SCIENTIFIC, AMGEN, abbvie, INTUITIVE, Lilly, Roche

As at March 31, 2021.

Scotia Plaza, 40 King Street West, Suite 3404, Toronto ON M5H3Y2
416.214.4884 | 1.844.370.4884 | www.evolveetfs.com

*For the period ending March 31, 2021. The indicated rates of return are the historical annual compound total returns net of fees (except for figures of one year or less, which are simple total returns) including changes in per unit value and reinvestment of all dividends or distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. The rates of return shown in the table are not intended to reflect future values of the ETF or returns on investment in the ETF. ETFs are not guaranteed, their values change frequently, and past performance may not be repeated.

Commissions, trailing commissions, management fees and expenses all may be associated with exchange traded funds (ETFs) and mutual funds. Please read the prospectus before investing. There are risks involved with investing in ETFs and mutual funds. Please read the prospectus for a complete description of risks relevant to the ETF and mutual fund. Investors may incur customary brokerage commissions in buying or selling ETF and mutual fund units. Investors should monitor their holdings, as frequently as daily, to ensure that they remain consistent with their investment strategies.